It's not always genetic damage that drives cancer, sometimes it's the chemical on-off switches known as epigenetic factors. MD Anderson's Jean-Pierre Issa explains.
First clinical trials begin soon to test new drugs against ovarian, endometrial and breast cancers that harbor dysfunctional PI3K pathways. MD Anderson's Gordon Mills explains.
Tumor genetics must be analyzed to personalize lung cancer treatment. Could escaped cancer cells replace invasive biopsies? MD Anderson's Roy Herbst explains.